Nanox Announces Third Quarter of 2024 Financial Results and Provides Business Update
Nanox (NASDAQ: NNOX) reported Q3 2024 financial results with revenue of $3.0 million, up from $2.5 million in Q3 2023. The company posted a net loss of $13.6 million, improved from $21.4 million loss year-over-year. Teleradiology services generated $2.6 million in revenue with a 13% gross profit margin. The company continues expanding US sales teams and deploying units globally, while progressing with FDA applications for full body scanning and CE Mark designation. Cash position stands at $57.1 million as of September 30, 2024, down from $82.8 million at end of 2023.
Nanox (NASDAQ: NNOX) ha riportato i risultati finanziari del terzo trimestre 2024 con un fatturato di 3,0 milioni di dollari, in aumento rispetto ai 2,5 milioni di dollari del terzo trimestre 2023. L'azienda ha registrato una perdita netta di 13,6 milioni di dollari, migliorata rispetto alla perdita di 21,4 milioni dell'anno precedente. I servizi di teleradiologia hanno generato un fatturato di 2,6 milioni di dollari con un margine di profitto lordo del 13%. L'azienda continua ad espandere i propri team di vendita negli Stati Uniti e a distribuire unita' globalmente, mentre prosegue con le domande FDA per la scansione del corpo intero e la designazione CE Mark. La posizione di cassa è di 57,1 milioni di dollari al 30 settembre 2024, in calo rispetto agli 82,8 milioni di dollari alla fine del 2023.
Nanox (NASDAQ: NNOX) reportó resultados financieros del tercer trimestre de 2024 con ingresos de 3,0 millones de dólares, un aumento desde los 2,5 millones de dólares en el tercer trimestre de 2023. La compañía publicó una pérdida neta de 13,6 millones de dólares, mejorando desde una pérdida de 21,4 millones año con año. Los servicios de teleradiología generaron 2,6 millones de dólares en ingresos con un margen de utilidad bruta del 13%. La compañía sigue expandiendo sus equipos de ventas en EE.UU. y desplegando unidades a nivel global, mientras avanza con las solicitudes a la FDA para la escaneado de cuerpo completo y la designación CE Mark. La posición de caja asciende a 57,1 millones de dólares a partir del 30 de septiembre de 2024, en comparación con los 82,8 millones de dólares a finales de 2023.
Nanox (NASDAQ: NNOX)는 2024년 3분기 재무 결과를 발표했으며, 수익은 300만 달러로 2023년 3분기 250만 달러에서 증가했습니다. 회사는 1,360만 달러의 순손실을 기록했으며, 이는 전년 대비 2,140만 달러의 손실에서 개선된 수치입니다. 원격 영상 서비스는 260만 달러의 수익을 창출했으며, 총 이익률은 13%입니다. 회사는 미국 판매 팀을 계속 확장하고 있으며, 전 세계적으로 유닛을 배포하는 동시에 전체 신체 스캔 및 CE 마크 지정에 대한 FDA 신청을 진행하고 있습니다. 현금 잔고는 2024년 9월 30일 기준으로 5,710만 달러로, 2023년 말의 8,280만 달러에서 감소했습니다.
Nanox (NASDAQ: NNOX) a rapporté les résultats financiers du troisième trimestre 2024 avec un chiffre d'affaires de 3,0 millions de dollars, en hausse par rapport à 2,5 millions de dollars au troisième trimestre 2023. L'entreprise a affiché une perte nette de 13,6 millions de dollars, en amélioration par rapport à une perte de 21,4 millions l'année précédente. Les services de téléradiologie ont généré 2,6 millions de dollars de chiffre d'affaires avec une marge brute de profit de 13 %. L'entreprise continue d’élargir ses équipes de vente aux États-Unis et de déployer des unités à l'échelle mondiale, tout en progressant dans ses demandes auprès de la FDA pour la scannérisation du corps entier et la désignation CE. La position de trésorerie s'élève à 57,1 millions de dollars au 30 septembre 2024, en baisse par rapport à 82,8 millions de dollars à la fin de 2023.
Nanox (NASDAQ: NNOX) hat die Finanzergebnisse für das dritte Quartal 2024 veröffentlicht, mit einem Umsatz von 3,0 Millionen Dollar, ein Anstieg von 2,5 Millionen Dollar im dritten Quartal 2023. Das Unternehmen verzeichnete einen Nettoverlust von 13,6 Millionen Dollar, eine Verbesserung gegenüber dem Verlust von 21,4 Millionen Dollar im Vorjahr. Die Teleradiologiedienste erzielten einen Umsatz von 2,6 Millionen Dollar mit einer Bruttogewinnmarge von 13%. Das Unternehmen erweitert weiterhin seine Verkaufsteams in den USA und setzt weltweit Einheiten ein, während es bei den FDA-Anträgen für Ganzkörper-Scans und der CE-Kennzeichnung Fortschritte macht. Die Liquiditätsposition liegt am 30. September 2024 bei 57,1 Millionen Dollar, Rückgang von 82,8 Millionen Dollar Ende 2023.
- Revenue increased 20% YoY to $3.0 million
- Net loss decreased by $7.8 million to $13.6 million
- Teleradiology revenue grew to $2.6 million from $2.2 million YoY
- Operating expenses decreased, with R&D costs down $1.3 million
- Gross loss widened to $2.8 million (93% margin) from $1.7 million (67% margin) YoY
- Cash position decreased by $25.7 million to $57.1 million since December 2023
- Imaging systems revenue declined to $29,000 from $99,000 YoY
- Negative cash flow from operations of $26.1 million
Insights
The Q3 2024 results reveal mixed signals for Nanox. While revenue grew to
The cash position has deteriorated significantly, with total cash and equivalents dropping to
The deployment progress and regulatory pathway present both opportunities and challenges. While the company reports "dozens of units deployed globally," specific installation numbers remain vague. The pending FDA approval for full body scanning and CE Mark designation are critical milestones that could significantly expand market opportunities. However, the low revenue from imaging systems (
Made progress deploying all components of the Nanox solution including Nanox.ARC and Nanox.AI
Expanded US sales and support staff a key component of global strategic growth plan
Management to host conference call and webcast Thursday, November 21, 2024 at 8:30 AM ET
PETACH TIKVA, Israel, Nov. 21, 2024 (GLOBE NEWSWIRE) -- November 21, 2024 — NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced results for the third quarter ended September 30, 2024 and provided a business update.
Recent Highlights:
- Generated
$3.0 million in revenue in the third quarter of 2024, compared to$2.5 million in the third quarter of 2023.
- Continued to expand the US sales and support teams, and made progress in deployment, with dozens of units deployed globally.
- Growth of the Nanox.AI business continued apace, signing new distribution agreements with SpinexMedical, and extending our agreements with users such as: Corewell Health, Dandelion health and Oxford University Hospitals extending the use of the Nanox.AI solutions.
- Multi-site clinical trial aimed at generating data supporting the clinical value of the Nanox.ARC is in progress at Beilinson hospital in Israel and in Ghana.
“I am more confident than ever in the future of Nanox as we accelerate the deployment of our Nanox.ARC and Nanox.AI technologies across the U.S. and international markets.” said Erez Meltzer, Nanox Chief Executive Officer and Acting Chairman. “The positive feedback from healthcare providers and patients underscores the transformative potential of our solutions across the healthcare continuum. On the regulatory front, we are working closely with the FDA on our application for full body scanning, and the European Union regulatory bodies to complete the CE Mark designation process. We believe securing these approvals will further solidify our position in the market, while significantly expanding our total addressable market. Coupled with our growing sales and support infrastructure we have established this past year, we are well-positioned to maintain our strong commercial momentum into 2025 and beyond.”
Financial results for three months ended September 30, 2024
For the three months ended September 30, 2024 (the “reported period”), the Company reported a net loss of
The Company reported revenue of
The Company’s gross loss during the reported period totaled
The Company’s revenue from teleradiology services for the reported period was
The Company’s GAAP gross profit from teleradiology services for the reported period was
During the reported period the Company generated revenue through the sales and deployment of its imaging systems which amounted to
The Company’s revenue from its AI solutions for the reported period was
Research and development expenses, net, for the reported period were
Sales and marketing expenses for the reported period were
General and administrative expenses for the reported period were
Non-GAAP net loss attributable to ordinary shares for the reported period was
Non-GAAP gross loss for the reported period was
The difference between the GAAP and non-GAAP financial measures above is mainly attributable to amortization of intangible assets, share-based compensation, change in contingent earnout liability, impairment of Goodwill, expenses related to an offering and legal fees in connection with the class-action litigation and the SEC investigation. A reconciliation between GAAP and non-GAAP financial measures for the three- and nine-months periods ended September 30, 2024, and 2023 is provided in the financial results that are part of this press release.
Liquidity and Capital Resources
As of September, 30, 2024, the Company had total cash, cash equivalents, restricted deposits and marketable securities of
Other Assets
As of September 30, 2024 the Company had property and equipment of
As of September, 30, 2024, the Company had intangible assets of
Shareholders’ Equity
As of September 30, 2024, the Company had approximately 58.5 million shares outstanding. As of December 31, 2023, the Company had approximately 57.8 million shares outstanding.
Conference Call and Webcast Details
Tuesday, November 21, 2024 @ 8:30am ET
Individuals interested in listening to the conference call may do so by joining the live webcast on the Investors section of the Nanox website under Events and Presentations. Alternatively, individuals can register online to receive a dial-in number and personalized PIN to participate in the call. An archived webcast of the event will be available for replay following the event.
About Nanox:
Nanox (NASDAQ: NNOX) is focused on driving the world’s transition to preventive health care by bringing a full solution of affordable medical imaging technologies based on advanced AI and novel digital source. Nanox’s vision encompasses expanding the reach of Nanox technology both within and beyond hospital settings, providing a seamless end-to-end solution from scan to diagnosis, leveraging AI for smarter diagnostics and maintaining a clinically-driven approach. The Nanox ecosystem includes Nanox.ARC – a multi-source Digital Tomosynthesis system that is cost-effective and user-friendly; Nanox.AI – an AI-based suite of algorithms that augment the readings of routine CT imaging to highlight early signs often related to chronic diseases; Nanox.CLOUD – a cloud-based software platform that manages and stores data collected by Nanox devices, and provides users with tools for in-depth imaging analysis; Nanox.MARKETPLACE – a proprietary decentralized marketplace through Nanox’s subsidiary, USARAD Holdings Inc., that provides remote access to radiology and cardiology experts, and a comprehensive teleradiology services platform. By improving early detection and treatment, Nanox aims to enhance its better health outcomes worldwide. For more information, please visit www.nanox.vision.
Forward-Looking Statements:
This press release may contain forward-looking statements that are subject to risks and uncertainties. All statements that are not historical facts contained in this press release are forward-looking statements. Such statements include, but are not limited to, those relating to the initiation, timing, progress and results of the Company’s research and development, manufacturing, and commercialization activities with respect to its X-ray source technology and the Nanox.ARC, the ability to realize the expected benefits of its recent acquisitions and the projected business prospects of the Company and the acquired companies. In some cases, you can identify forward-looking statements by terminology such as “can,” “might,” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “should,” “could,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on information the Company has when those statements are made or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to (i) Nanox’s ability to continue to develop of the Nanox imaging system; (ii) Nanox’s ability to successfully demonstrate the feasibility of its technology for commercial applications; (iii) Nanox’s expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding its technology, the Nanox.ARC and Nanox.CLOUD from regulatory agencies worldwide and its ongoing compliance with applicable quality standards and regulatory requirements; (iv) Nanox’s ability to realize the anticipated benefits of acquisitions, which may be affected by, among other things, competition, brand recognition, the ability of the acquired companies to grow and manage growth profitably and retain their key employees; (v) Nanox’s ability to enter into and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture the Nanox.ARC; (vi) the market acceptance of the Nanox imaging system and the proposed pay-per-scan business model; (vii) Nanox’s expectations regarding collaborations with third-parties and their potential benefits; and (viii) Nanox’s ability to conduct business globally; (ix) changes in global, political, economic, business, competitive, market and regulatory forces, including the continuation and escalation of the military conflicts in Israel and current war between Israel and Hamas; (x) the costs incurred with respect to and the outcome of litigation Nanox is currently subject to and any similar or other claims and potential litigation it may be subject to in the future; and (xi) risks related to business interruptions resulting from the COVID-19 pandemic or similar public health crises, among other things.
For a discussion of other risks and uncertainties, and other important factors, any of which could cause Nanox’s actual results to differ from those contained in the Forward-Looking Statements, see the section titled “Risk Factors” in Nanox’s Annual Report on Form 20-F for the year ended December 31, 2023, and subsequent filings with the U.S. Securities and Exchange Commission. The reader should not place undue reliance on any forward-looking statements included in this press release.
Except as required by law, Nanox undertakes no obligation to update publicly any forward-looking statements after the date of this press release to conform these statements to actual results or to changes in the Company’s expectations.
Non-GAAP Financial Measures
This press release includes information about certain financial measures that are not prepared in accordance with generally accepted accounting principles in the United States (“GAAP”), including non-GAAP net loss attributable to ordinary shares, non-GAAP cost of revenue, non-GAAP gross profit, non-GAAP gross profit margin, non-GAAP research and development expenses, non-GAAP sales and marketing expenses, non-GAAP general and administrative expenses and non-GAAP basic and diluted loss per share. These non-GAAP measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies. These non-GAAP measures are adjusted for (as applicable) amortization of intangible assets, share-based compensation expenses,impairment of Goodwill, change in contingent earnout liability and legal fees in connection with class-action litigation and the SEC investigation. The Company’s management and board of directors utilize these non-GAAP financial measures to evaluate the Company’s performance. The Company provides these non-GAAP measures of the Company’s performance to investors because management believes that these non-GAAP financial measures, when viewed with the Company’s results under GAAP and the accompanying reconciliations, are useful in identifying underlying trends in ongoing operations. However, these non-GAAP measures are not measures of financial performance under GAAP and, accordingly, should not be considered as alternatives to GAAP measures as indicators of operating performance. Further, these non-GAAP measures should not be considered measures of the Company’s liquidity. A reconciliation of certain GAAP to non-GAAP financial measures has been provided in the tables included in this press release.
| NANO-X IMAGING LTD. UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (U.S. dollars in thousands except share and per share data) | ||||||||
| September 30, 2024 | December 31, 2023 | |||||||
| U.S. Dollars in thousands | ||||||||
| Assets | ||||||||
| CURRENT ASSETS: | ||||||||
| Cash and cash equivalents | 38,193 | 56,377 | ||||||
| Restricted deposit | 46 | 46 | ||||||
| Marketable securities | 18,517 | 26,006 | ||||||
| Accounts receivables net of allowance for credit losses of | 1,492 | 1,484 | ||||||
| Inventories | 1,032 | 2,356 | ||||||
| Prepaid expenses | 230 | 1,274 | ||||||
| Other current assets | 930 | 1,092 | ||||||
| TOTAL CURRENT ASSETS | 60,440 | 88,635 | ||||||
| NON-CURRENT ASSETS: | ||||||||
| Restricted deposit | 330 | 327 | ||||||
| Property and equipment, net | 44,657 | 42,343 | ||||||
| Operating lease right-of-use asset | 3,961 | 4,573 | ||||||
| Intangible assets | 72,648 | 80,607 | ||||||
| Other non-current assets | 1,905 | 2,163 | ||||||
| TOTAL NON-CURRENT ASSETS | 123,501 | 130,013 | ||||||
| TOTAL ASSETS | 183,941 | 218,648 | ||||||
| Liabilities and Shareholders’ Equity | ||||||||
| CURRENT LIABILITIES: | ||||||||
| Current maturities of long-term loan | 3,410 | 3,490 | ||||||
| Accounts payable | 1,331 | 3,303 | ||||||
| Accrued expenses | 3,300 | 3,920 | ||||||
| Deferred revenue | 297 | 543 | ||||||
| Current maturities of operating lease liabilities | 737 | 861 | ||||||
| Other current liabilities | 3,953 | 3,407 | ||||||
| TOTAL CURRENT LIABILITIES | 13,028 | 15,524 | ||||||
| NON-CURRENT LIABILITIES: | ||||||||
| Non-current operating lease liabilities | 3,661 | 4,045 | ||||||
| Deferred tax liability | 2,670 | 2,953 | ||||||
| Other long-term liabilities | 695 | 612 | ||||||
| TOTAL NON-CURRENT LIABILITIES | 7,026 | 7,610 | ||||||
| TOTAL LIABILITIES | 20,054 | 23,134 | ||||||
| COMMITMENTS AND CONTINGENCIES (Note 3) | ||||||||
| SHAREHOLDERS’ EQUITY: | ||||||||
| Ordinary Shares, par value NIS 0.01 per share 100,000,000 authorized at September 30, 2024 and December 31 2023,58,521,934 and 57,778,628 issued and outstanding at September 30, 2024 and December 31, 2023, respectively | 167 | 165 | ||||||
| Additional paid-in capital | 523,396 | 515,887 | ||||||
| Accumulated other comprehensive loss | 12 | (305 | ) | |||||
| Accumulated deficit | (359,688 | ) | (320,233 | ) | ||||
| TOTAL SHAREHOLDERS’ EQUITY | 163,887 | 195,514 | ||||||
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | 183,941 | 218,648 | ||||||
| The accompanying notes are an integral part of the unaudited condensed consolidated financial statements | ||||||||
| NANO-X IMAGING LTD. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (U.S. dollars in thousands except share and per share data) | ||||||||||||||||
| Nine Months Ended September 30, | Three Months Ended September 30, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| REVENUE | 8,283 | 7,508 | 3,031 | 2,479 | ||||||||||||
| COST OF REVENUE | 16,002 | 12,384 | 5,843 | 4,141 | ||||||||||||
| GROSS LOSS | (7,719 | ) | (4,876 | ) | (2,812 | ) | (1,662 | ) | ||||||||
| OPERATING EXPENSES: | ||||||||||||||||
| Research and development, net | 14,781 | 19,237 | 4,749 | 6,038 | ||||||||||||
| Sales and marketing | 2,521 | 3,134 | 887 | 1,146 | ||||||||||||
| General and administrative | 16,669 | 20,481 | 5,711 | 5,047 | ||||||||||||
| Goodwill impairment | - | 7,420 | - | 7,420 | ||||||||||||
| Change in contingent earnout liability | - | (4,506 | ) | - | 17 | |||||||||||
| Other expenses (income), net | 81 | 1,260 | (20 | ) | 663 | |||||||||||
| TOTAL OPERATING EXPENSES | 34,052 | 47,026 | 11,327 | 20,331 | ||||||||||||
| OPERATING LOSS | (41,771 | ) | (51,902 | ) | (14,139 | ) | (21,993 | ) | ||||||||
| REALIZED INCOME (LOSS) FROM SALE OF MARKETABLE SECURITIES | 2 | (178 | ) | 2 | - | |||||||||||
| FINANCIAL INCOME, net | 2,050 | 1,292 | 404 | 511 | ||||||||||||
| OPERATING LOSS BEFORE INCOME TAXES | (39,719 | ) | (50,788 | ) | (13,733 | ) | (21,482 | ) | ||||||||
| INCOME TAX BENEFIT | 264 | 260 | 94 | 79 | ||||||||||||
| NET LOSS | (39,455 | ) | (50,528 | ) | (13,639 | ) | (21,403 | ) | ||||||||
| BASIC AND DILUTED LOSS PER SHARE | (0.68 | ) | (0.90 | ) | (0.23 | ) | (0.37 | ) | ||||||||
| Weighted average number of basic and diluted ordinary shares outstanding (in thousands) | 58,182 | 55,900 | 58,624 | 57,148 | ||||||||||||
| Comprehensive Loss: | ||||||||||||||||
| Net Loss | (39,455 | ) | (50,528 | ) | (13,639 | ) | (21,403 | ) | ||||||||
| Other comprehensive loss: | ||||||||||||||||
| Reclassification of net income (losses) realized in income statement | 2 | (178 | ) | 2 | (178 | ) | ||||||||||
| Unrealized gain from available for-sale securities | 315 | 1,506 | 62 | 545 | ||||||||||||
| Total comprehensive loss | (39,138 | ) | (49,200 | ) | (13,575 | ) | (21,036 | ) | ||||||||
| The accompanying notes are an integral part of the unaudited condensed consolidated financial statements | ||||||||||||||||
| NANO-X IMAGING LTD. UNAUDITED CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY (U.S. dollars in thousands, except share and per share data) | ||||||||||||||||||||||||
| Ordinary shares | Additional | Accumulated other | ||||||||||||||||||||||
| Number of shares | Amount | paid-in capital | comprehensive loss | Accumulated deficit | Total | |||||||||||||||||||
| BALANCE AT JANUARY 1, 2024 | 57,778,628 | 165 | 515,887 | (305 | ) | (320,233 | ) | 195,514 | ||||||||||||||||
| Changes during the period: | ||||||||||||||||||||||||
| Issuance of ordinary shares upon exercise of options | 743,306 | 2 | 1,664 | - | - | 1,666 | ||||||||||||||||||
| Share-based compensation | - | - | 5,845 | - | - | 5,845 | ||||||||||||||||||
| Unrealized gain from marketable securities | - | - | - | 317 | - | 317 | ||||||||||||||||||
| Net loss for the period | - | - | - | - | (39,455 | ) | (39,455 | ) | ||||||||||||||||
| BALANCE AT SEPTEMBER 30, 2024 | 58,521,934 | 167 | 523,396 | 12 | (359,688 | ) | 163,887 | |||||||||||||||||
| Accumulated | ||||||||||||||||||||||||
| Ordinary shares | Additional | other | ||||||||||||||||||||||
| Number of | paid-in | comprehensive | Accumulated | |||||||||||||||||||||
| shares | Amount | capital | deficit | deficit | Total | |||||||||||||||||||
| U.S. Dollars in thousands | ||||||||||||||||||||||||
| BALANCE AT JANUARY 1, 2023 | 55,094,237 | 158 | 477,953 | (1,974 | ) | (259,457 | ) | 216,680 | ||||||||||||||||
| Changes during the period: | ||||||||||||||||||||||||
| Issuance of ordinary shares and warrants, net of issuance expenses ** | 2,142,858 | 6 | 27,133 | - | - | 27,139 | ||||||||||||||||||
| Issuance of ordinary shares upon exercise of options | 224,938 | * | 870 | - | - | 870 | ||||||||||||||||||
| Issuance of ordinary shares under settlement agreement with former shareholders of USARAD Holding Inc. | 255,392 | 1 | 1,560 | - | - | 1,561 | ||||||||||||||||||
| Other comprehensive gain | - | - | - | 1,328 | - | 1,328 | ||||||||||||||||||
| Share-based compensation | - | - | 4,981 | - | - | 4,981 | ||||||||||||||||||
| Net loss for the period | - | - | - | - | (50,528 | ) | (50,528 | ) | ||||||||||||||||
| BALANCE AT SEPTEMBER 30, 2023 | 57,717,425 | 165 | 512,497 | (646 | ) | (309,985 | ) | 202,031 | ||||||||||||||||
| * Less than | ||||||||||||||||||||||||
| ** Issuance expenses totaled to | ||||||||||||||||||||||||
| Accumulated | ||||||||||||||||||||||||
| Ordinary shares | Additional | other | ||||||||||||||||||||||
| Number of | paid-in | comprehensive | Accumulated | |||||||||||||||||||||
| shares | Amount | capital | deficit | deficit | Total | |||||||||||||||||||
| U.S. Dollars in thousands | ||||||||||||||||||||||||
| BALANCE AT JULY 1, 2024 | 58,497,123 | 167 | 521,069 | (52 | ) | (346,049 | ) | 175,135 | ||||||||||||||||
| Changes during the period: | ||||||||||||||||||||||||
| Issuance of ordinary shares upon exercise of options | 24,811 | * | 60 | - | - | 60 | ||||||||||||||||||
| Other comprehensive gain | - | - | - | 64 | - | 64 | ||||||||||||||||||
| Share-based compensation | - | - | 2,267 | - | - | 2,267 | ||||||||||||||||||
| Net loss for the period | - | - | - | - | (13,639 | ) | (13,639 | ) | ||||||||||||||||
| BALANCE AT SEPTEMBER 30, 2024 | 58,521,934 | 167 | 523,396 | 12 | (359,688 | ) | 163,887 | |||||||||||||||||
| * Less than | ||||||||||||||||||||||||
| Accumulated | ||||||||||||||||||||||||
| Ordinary shares | Additional | other | ||||||||||||||||||||||
| Number of | paid-in | comprehensive | Accumulated | |||||||||||||||||||||
| shares | Amount | capital | deficit | deficit | Total | |||||||||||||||||||
| U.S. Dollars in thousands | ||||||||||||||||||||||||
| BALANCE AT JULY 1, 2023 | 55,559,767 | 159 | 482,971 | (1,013 | ) | (288,582 | ) | 193,535 | ||||||||||||||||
| Changes during the period: | ||||||||||||||||||||||||
| Issuance of ordinary shares and warrants, net of issuance expenses ** | 2,142,858 | 6 | 27,133 | - | - | 27,139 | ||||||||||||||||||
| Issuance of ordinary shares upon exercise of options | 14,800 | * | 275 | - | - | 275 | ||||||||||||||||||
| Other comprehensive gain | - | - | - | 367 | - | 367 | ||||||||||||||||||
| Share-based compensation | - | - | 2,118 | - | - | 2,118 | ||||||||||||||||||
| Net loss for the period | - | - | - | - | (21,403 | ) | (21,403 | ) | ||||||||||||||||
| BALANCE AT SEPTEMBER 30, 2023 | 57,717,425 | 165 | 512,497 | (646 | ) | (309,985 | ) | 202,031 | ||||||||||||||||
| * Less than | ||||||||||||||||||||||||
| ** Issuance expenses totaled to | ||||||||||||||||||||||||
| The accompanying notes are an integral part of the unaudited condensed consolidated financial statements | ||||||||||||||||||||||||
| NANO-X IMAGING LTD. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (U.S. dollars in thousands) | ||||||||
| Nine Months Ended September 30, | ||||||||
| 2024 | 2023 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net loss for the period | (39,455 | ) | (50,528 | ) | ||||
| Adjustments required to reconcile net loss to net cash used in operating activities: | ||||||||
| Share-based compensation | 5,845 | 4,981 | ||||||
| Amortization of intangible assets | 7,959 | 7,959 | ||||||
| Impairment of Goodwill | - | 7,420 | ||||||
| Exchange rate differentials | (108 | ) | (228 | ) | ||||
| Change in contingent earnout liability | - | (4,506 | ) | |||||
| Depreciation | 839 | 753 | ||||||
| Deferred tax liability, net | (283 | ) | (283 | ) | ||||
| Realized loss (income) from sale of marketable securities | (2 | ) | 178 | |||||
| Amortization of premium, discount and accrued interest on marketable securities | (113 | ) | 717 | |||||
| Impairment of property and equipment | 116 | 883 | ||||||
| Changes in Operating Assets and Liabilities: | ||||||||
| Accounts receivable | (8 | ) | (186 | ) | ||||
| Inventories | (140 | ) | - | |||||
| Prepaid expenses and other current assets | 1,206 | 2,395 | ||||||
| Other non-current assets | 183 | 38 | ||||||
| Accounts payable | (1,972 | ) | (1,378 | ) | ||||
| Operating lease assets and liabilities | 104 | (15 | ) | |||||
| Accrued expenses and other liabilities | (74 | ) | (477 | ) | ||||
| Deferred Revenue | (246 | ) | (63 | ) | ||||
| Other long-term liabilities | 83 | 77 | ||||||
| Net cash used in operating activities | (26,066 | ) | (32,263 | ) | ||||
| CASH FLOWS PROVIDED BY INVESTING ACTIVITIES: | ||||||||
| Purchase of property and equipment | (1,730 | ) | (2,775 | ) | ||||
| Purchase of marketable securities | (33,017 | ) | - | |||||
| Proceeds from maturity of marketable securities | 40,938 | 35,112 | ||||||
| Proceeds from sale of marketable securities | - | 822 | ||||||
| Net cash provided by investing activities | 6,191 | 33,159 | ||||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Payment due to settlement of contingent earnout liabilities | - | (790 | ) | |||||
| Proceeds from issuance of ordinary shares and warrants, net of issuance expenses | - | 27,139 | ||||||
| Proceeds from issuance of ordinary shares upon exercise of options | 1,666 | 870 | ||||||
| Net cash provided by/(used in) financing activities | 1,666 | 27,219 | ||||||
| EFFECT OF CHANGES IN EXCHANGE RATES ON CASH AND CASH EQUIVALENTS AND RESTRICTED CASH EQUIVALENTS | 25 | 93 | ||||||
| NET CHANGE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH EQUIVALENTS | (18,184 | ) | 28,208 | |||||
| CASH AND CASH EQUIVALENTS AND RESTRICTED CASH EQUIVALENTS AT BEGINNING OF THE PERIOD | 56,377 | 38,529 | ||||||
| CASH AND CASH EQUIVALENTS AND RESTRICTED CASH EQUIVALENTS AT END OF THE PERIOD | 38,193 | 66,737 | ||||||
| SUPPLEMENTARY INFORMATION ON ACTIVITIES INVOLVING CASH FLOWS | ||||||||
| Cash paid for interest | 106 | 99 | ||||||
| Cash paid for income taxes | 51 | 22 | ||||||
| SUPPLEMENTARY INFORMATION ON ACTIVITIES NOT INVOLVING CASH FLOWS - | ||||||||
| Ordinary shares issued in connection with earnout liability | - | 1,561 | ||||||
| Operating lease liabilities arising from obtaining operating right-of use assets | - | 2,495 | ||||||
| RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH EQUIVALENTS: | ||||||||
| Cash and cash equivalents | 38,193 | 66,384 | ||||||
| Restricted cash equivalents | - | 353 | ||||||
| Total cash, cash equivalents and restricted cash equivalents | 38,193 | 66,737 | ||||||
| The accompanying notes are an integral part of the unaudited condensed consolidated financial statements | ||||||||
| UNAUDITED RECONCILIATION OF GAAP AND NON-GAAP RESULTS (U.S. dollars in thousands (except per share data)) |
Use of Non-GAAP Financial Measures
The unaudited condensed consolidated financial information is prepared in conformity with GAAP. The Company uses information about certain financial measures that are not prepared in accordance with GAAP, including non-GAAP net loss attributable to ordinary shares, non-GAAP cost of revenue, non-GAAP gross profit, non-GAAP gross profit margin, non-GAAP research and development expenses non-GAAP sales and marketing expenses, non-GAAP general and administrative expenses, Non-GAAP other expenses (income) and non-GAAP basic and diluted loss per share. These non-GAAP measures are adjusted for (as applicable) amortization of intangible assets, share-based compensation expenses, impairment of Goodwill, change in contingent earnout liability, expenses related to an offering and legal fees in connection with the class-action litigation and the SEC investigation. The Company believes that separate analysis and exclusion of the one-off or non-cash impact of the above reconciling items (as applicable) adds clarity to the constituent parts of its performance. The Company reviews these non-GAAP financial measures together with GAAP financial measures to obtain a better understanding of its operating performance. It uses the non-GAAP financial measures for planning, forecasting, and measuring results against the forecast. The Company believes that the non-GAAP financial measures are useful supplemental information for investors and analysts to assess its operating performance. However, these non-GAAP measures are not measures of financial performance under GAAP and, accordingly, should not be considered as alternatives to GAAP measures as indicators of operating performance.
Reconciliation of GAAP net loss attributable to ordinary shares to Non-GAAP net loss attributable to ordinary shares and Non-GAAP basic and diluted loss per share (U.S. dollars in thousands)
| Nine Months Ended | Three Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| GAAP net loss attributable to ordinary shares | 39,455 | 50,528 | 13,639 | 21,403 | ||||||||||||
| Non-GAAP adjustments: | ||||||||||||||||
| Less (Add): Class-action litigation and SEC investigation | 76 | 4,203 | - | (214 | ) | |||||||||||
| Less: Amortization of intangible assets | 7,959 | 7,959 | 2,653 | 2,653 | ||||||||||||
| Less: Impairment of goodwill | - | 7,420 | 7,420 | |||||||||||||
| Less: Offering expenses | 420 | - | - | - | ||||||||||||
| Less (Add): Change in the fair value of earn out liabilities’ obligation | - | (4,506 | ) | - | 17 | |||||||||||
| Less: accrual in connection with the estimated settlement of the SEC investigation | - | 650 | - | - | ||||||||||||
| Less: Share-based compensation | 5,845 | 4,981 | 2,267 | 2,118 | ||||||||||||
| Non-GAAP net loss attributable to ordinary shares | 25,155 | 29,821 | 8,719 | 9,409 | ||||||||||||
| BASIC AND DILUTED LOSS PER SHARE | 0.43 | 0.53 | 0.15 | 0.16 | ||||||||||||
| WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES (in thousands) | 58,182 | 55,900 | 58,624 | 57,148 | ||||||||||||
Reconciliation of GAAP cost of revenue to Non-GAAP cost of revenue (U.S. dollars in thousands)
| GAAP cost of revenue | 16,002 | 12,384 | 5,843 | 4,141 | ||||||||||||
| Non-GAAP adjustments: | ||||||||||||||||
| Amortization of intangible assets | 7,668 | 7,668 | 2,556 | 2,556 | ||||||||||||
| Share-based compensation | 173 | 41 | 61 | 13 | ||||||||||||
| Non-GAAP cost of revenue | 8,161 | 4,675 | 3,226 | 1,572 | ||||||||||||
Reconciliation of GAAP gross loss to Non-GAAP gross profit (U.S. dollars in thousands)
| GAAP gross loss | (7,719 | ) | (4,876 | ) | (2,812 | ) | (1,662 | ) | ||||||||
| Non-GAAP adjustments: | ||||||||||||||||
| Amortization of intangible assets | 7,668 | 7,668 | 2,556 | 2,556 | ||||||||||||
| Share-based compensation | 173 | 41 | 61 | 13 | ||||||||||||
| Non-GAAP gross profit (loss) | 122 | 2,833 | (195 | ) | 907 | |||||||||||
Reconciliation of GAAP gross loss margin to Non-GAAP gross profit margin (in percentage of revenue)
| GAAP gross loss margin | (93 | )% | (65 | )% | (93 | )% | (67 | )% | ||||||||
| Non-GAAP adjustments: | ||||||||||||||||
| Amortization of intangible assets | 92 | % | 102 | % | 85 | % | 103 | % | ||||||||
| Share-based compensation | 2 | % | 1 | % | 2 | % | 1 | % | ||||||||
| Non-GAAP gross profit (loss) margin | 1 | % | 38 | % | (6 | )% | 37 | % | ||||||||
Reconciliation of GAAP research and development, expenses to Non-GAAP research and development expenses, net (U.S. dollars in thousands)
| GAAP research and development expenses, net | 14,781 | 19,237 | 4,749 | 6,038 | ||||||||||||
| Non-GAAP adjustments: | ||||||||||||||||
| Share-based compensation | 2,039 | 2,893 | 723 | 1,158 | ||||||||||||
| Non-GAAP research and development expenses, net | 12,742 | 16,344 | 4,026 | 4,880 | ||||||||||||
Reconciliation of GAAP sales and marketing expenses to Non-GAAP sales and marketing expenses (U.S. dollars in thousands)
| GAAP sales and marketing expenses | 2,521 | 3,134 | 887 | 1,146 | ||||||||||||
| Non-GAAP adjustments: | ||||||||||||||||
| Amortization of intangible assets | 291 | 291 | 97 | 97 | ||||||||||||
| Share-based compensation | 572 | 334 | 222 | 149 | ||||||||||||
| Non-GAAP sales and marketing expenses | 1,658 | 2,509 | 568 | 900 | ||||||||||||
Reconciliation of GAAP general and administrative expenses to Non-GAAP general and administrative expenses (U.S. dollars in thousands)
| GAAP general and administrative expenses | 16,669 | 20,481 | 5,711 | 5,047 | ||||||||||||
| Non-GAAP adjustments: | ||||||||||||||||
| Class-action litigation and SEC investigation | 76 | 4,203 | - | (214 | ) | |||||||||||
| Offering expenses | 420 | - | - | - | ||||||||||||
| Share-based compensation | 3,061 | 1,713 | 1,261 | 798 | ||||||||||||
| Non-GAAP general and administrative expenses | 13,112 | 14,565 | 4,450 | 4,463 | ||||||||||||
Reconciliation of GAAP other expenses to Non-GAAP other expenses (income) (U.S. dollars in thousands)
| GAAP other expenses (income) | 81 | 1,260 | (20 | ) | 663 | |||||||||||
| Non-GAAP adjustments: | ||||||||||||||||
| Accrual in connection with the estimated settlement of the SEC investigation | - | 650 | - | - | ||||||||||||
| Non-GAAP other expenses (income) | 81 | 610 | (20 | ) | 663 | |||||||||||
FAQ
What was Nanox (NNOX) revenue in Q3 2024?
How much cash does Nanox (NNOX) have as of Q3 2024?
What was Nanox (NNOX) net loss in Q3 2024?
How much revenue did Nanox (NNOX) generate from teleradiology services in Q3 2024?
